Navigation Links
University of Washington Leads All SynCardia Certified Centers with 10 Implants of the Total Artificial Heart in 2012
Date:12/6/2012

TUCSON, Ariz., Dec. 6, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University of Washington (UW) Medical Center in Seattle has performed 10 implants of the SynCardia temporary Total Artificial Heart so far in 2012, the most of any SynCardia Certified Center this year. It also marks a new record for number of implants performed by a hospital during its first year as a SynCardia Certified Center.

(Photo: http://photos.prnewswire.com/prnh/20121206/LA24989)

Watch video of Dr. Mokadam discussing the Total Artificial Heart and patient Chris Marshall - http://www.syncardia.com/Educational/uw-medicine-patient-gets-total-artificial-heart-and-patient-chris-marshall.html

"We utilize this device to support patients in whom left ventricular assist device (LVAD) support would be ineffective or contraindicated," said Dr. Nahush A. Mokadam, the co-director of heart transplantation and director of mechanical circulatory support at UW Medical Center. "We have implanted patients with biventricular failure with refractory ventricular tachycardia, restrictive cardiomyopathy, giant cell myocarditis, post-infarct ventricular septal defect, multiple LVAD thromboses and unreconstructable aortomitral endocarditis to name a few, and they have benefitted greatly from this technology."

In January, UW Medical Center performed its first two implants of the SynCardia Total Artificial Heart during a three-day span. In March, UW became the first hospital in the Pacific Northwest to discharge a SynCardia Total Artificial Heart patient using the Freedom® portable driver. The patient, avid hiker Chris Marshall, logged more than 600 miles while he waited for his donor heart. On Sept. 12, he was successfully bridged to a heart transplant after 219 days of support. Currently, UW has four Total Artificial Heart patients waiting for a matching donor heart.

"The availability of the portable driver has given our patients the opportunity to be discharged while awaiting transplantation," said Dr. Mokadam. "This is a great advance for our program. We look forward to when the smaller devices under development become available. It will allow this lifesaving technology to be offered to a wider patient population that is currently being undertreated."

The current 70cc Total Artificial Heart fits a majority of men and some women. It is designed for use in patients with a Body Surface Area (BSA) of 1.7m² or greater. SynCardia is currently developing a smaller 50cc Total Artificial Heart designed for patients with a BSA of 1.2-1.7m².

There are currently 74 SynCardia Certified Centers worldwide, including 39 in the U.S. There are an additional 30 hospitals currently undergoing SynCardia's four-phase certification process.

The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

The 50cc Total Artificial Heart is not for Human Use. This product is in the research and development phase and will not be available for sale in the United States or Europe until all regulatory requirements have been met.

Like SynCardia on http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – http://twitter.com/SynCardia

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart… read more


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
2. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
3. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
4. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
5. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
6. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
7. Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center Announce the Formation of the SRT University™ Comprehensive Education Series for Practitioners, Healthcare Professionals, and Patients
8. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
9. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
10. Oregon State University Launches New Online Learning System For Pharmacy Managers
11. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):